Since 2000, new century, biomedicine had great progress at both scientific and technical levels. Among “breakthrough of the year” in
Science every year, we could conclude three important hot topics in biomedicine as follows. The first topic is Genome editing technique CRISPR/Cas (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated system). As a genome editing method, CRISPR/Cas was the top breakthrough in 2015. The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages that provides a form of acquired immunity. At beginning, CRISPR described segments of prokaryotic DNA containing short, repetitive base sequences in ancient bacteria (
Horvath & Barrangou, 2010). Later, the group of Jennifer Doudna induced CRISPR/Cas9 as a tool to cut DNA with crRANs in 2012 (Jinek et al.), and then the group of Feng Zhang applied CRISPR/Cas9 into eucaryotic cells in 2013 (
Cong et al., 2013). The group of Ma et al. (2017) describe the correction of a pathogenic gene mutation in human embryos with CRISPR/Cas9. Cox et al. (2017) proved that RNA can be edited with CRISPR-Cas13 to correct disease-relevant human mutations and proposed an RNA-editing platform named REPAIR. While another nuclease Cpf1 was discovered in 2015 then CRISPR/Cpf1 became another CRISPR system (
Zetsche et al., 2015). Yan et al. (2019) systematically discovered additional subtypes of type V CRISPR-Cas systems. The diversity, modularity, and efficacy of CRISPR-Cas systems are driving a biotechnological revolution and CRISPR-Cas guides the future of genetic engineering (
Knott & Doudna, 2018). The second theme is Stem cell technique iPS cell. As a type of pluripotent stem cell, the iPS cell technique was selected into new breakthrough in both 2012 and 2016. The iPS cell technique was pioneered by Shinya Yamanaka’s lab in Kyoto, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells (
Takahashi, 2006), on which Yamanaka was awarded the 2012 Nobel Prize along with Sir John Gurdon for their discovery that mature cells can be reprogrammed to become pluripotent. Since then, researchers have found a variety of more optimal induction methods (
Anokye-Danso et al., 2011;
Ma, Kong, & Zhu, 2017). At the meantime, researchers turned to introduce disease-associated mutations into a sample of iPS cells through gene editing. Paquet et al. (2016) generated cells with precise combinations of Alzheimer’s-associated mutations by introducing specific point mutations into iPS cells using CRISPR. The iPS cells have wide application perspectives in drug discovery and disease modelling (
Scudellari, 2016). The last topic is Synthetic biology and artificial life. This is an interdisciplinary branch of biology and engineering, which was selected into new breakthrough in 2010. Synthetic biologists come in two broad classes. One uses unnatural molecules to reproduce emergent behaviors from natural biology, with the goal of creating artificial life. The other seeks interchangeable parts from natural biology to assemble into systems that function unnaturally (
Benner & Sismour, 2005). Gibson et al. (2010) introduced their study about the Creation of a bacterial cell controlled by a chemically synthesized genome. Esvelt and Wang (2013) think Genome-modification technologies enable the rational engineering and perturbation of biological systems, such as CRISPR/Cas. Cameron, Bashor and Collins (2014) reviews the history of synthetic biology and points out that the field of synthetic biology has chartered many notable achievements and is poised to transform biotechnology and medicine.